Tags : Chronic Kidney Disease

Akebia Presents Results of Vadadustat in P-lll INNO2VATE Program for

Shots: The global program includes two P-III studies assessing vadadustat (PO) vs darbepoetin alfa (inj.) in a ratio (1:1) in incident dialysis patients (Correction/Conversion) and prevalent dialysis patients (Conversion), in ~3,923 adult patients on dialysis with anemia due to CKD The presentation expands on previously reported positive data showing vadadustat achieved clear and consistent results […]Read More

Novo Nordisk Collaborates with Evotec to Develop Therapies Targeting Chronic

Shots: Evotec to receive $179M/ product as upfront, research funding and milestones along with the royalties on sales of the therapies while Novo Nordisk will lead the clinical development and commercialization of the therapies The companies will share responsibilities during drug discovery and pre-clinical development and will jointly identify and develop novel targets based on […]Read More

AstraZeneca Report Results of Farxiga in P-III DAPA-CKD Study for

Shots: The P-III DAPA-CKD involve assessing of Farxiga ((dapagliflozin, 10mg, qd) + SOC vs PBO in 4,304 patients with CKD Stages 2–4 and elevated urinary albumin excretion, with and without T2D The study met its 1EPs i.e. worsening of renal function or risk of death (defined as a composite of an eGFR decline ≥50%, the […]Read More

Astellas and FibroGen Report EMA’s Acceptance of MAA for Roxadustat

Shots: The MAA is supported by P-III program which includes 9000+ patients globally and data from DOLOMITES study, results of which will be disclosed this year. Results of P-III program demonstrated that the therapy is efficacious in increasing & maintaining target hemoglobin levels with reduction in the use of IV iron in patients with CKD […]Read More

AstraZeneca Reports Results of Roxadustat in P-III OLYMPUS and ROCKIES

Shots: The P-III OLYMPUS study involve assessing of Roxadustat vs PBO in 2,781 patients with anaemia (Hb<10.0g/dL) in a ratio (1:1) in non-dialysis-dependent -CKD stages, resulted in improvement in Hb levels (1.75g/dL vs 0.40g/dL) and improvement in Hb levels in patients with elevated hsCRP levels > 5mg/L (1.73 g/dL vs 0.62g/dL) The P-III ROCKIES study […]Read More